Urology Times Innovation Celebration Video Series : Episode 14
Video
Urology Times 50 Innovations Series: Cryotherapy for kidney and prostate cancer
Author(s):
"Cryotherapy was the first energy source that we were able to ablate tissues with in either the kidney or prostate and understand what that ablation would do," says J. Stephen Jones, MD, FACS.
Video Player is loading.
Urology Times® is celebrating its 50th anniversary in 2022. To mark the occasion, we are highlighting 50 of the top innovations and developments that have transformed the field of urology over the past 50 years. In this installment, J. Stephen Jones, MD, FACS, discusses the development of cryotherapy for the treatment of kidney and prostate cancers. Jones is president and CEO of Inova Health System.
Related Videos
Dr Louise Kostos on the rapidly evolving prostate cancer treatment landscape
An expert’s view on combination ARPI/ADT and long-term toxicity in prostate cancer
Darren Feldman, MD, on study of 177Lu-girentuximab plus nivolumab for ccRCC
Rana McKay, MD, on the role of radium-223 in the modern era
Dr Louise Kostos discusses PSA kinetics in mHSPC
The importance of PSADT in high-risk, biochemically recurrent prostate cancer
Neeraj Agarwal, MD, outlines data on enzalutamide plus talazoparib in mCRPC
Expert discusses triplet regimens in metastatic hormone-sensitive prostate cancer
Alicia Morgans, MD, MPH, on PSADT awareness and prostate cancer treatment initiation
Dr Louise Kostos discusses combination therapies in mHSPC
Related Content
